Antidepressant use during pregnancy and psychiatric disorders in offspring: Danish nationwide register based cohort study by Liu, Xiaoqin et al.
the bmj | BMJ 2017;358:j3668 | doi: 10.1136/bmj.j3668 1
RESEARCH
Antidepressant use during pregnancy and psychiatric disorders 
in offspring: Danish nationwide register based cohort study
Xiaoqin Liu,1 Esben Agerbo,1,2,3 Katja G Ingstrup,1 Katherine Musliner,1,3  
Samantha Meltzer-Brody,4 Veerle Bergink,1,5 Trine Munk-Olsen,1
ABSTRACT
OBJECTIVE
To investigate the association between in utero 
exposure to antidepressants and risk of psychiatric 
disorders.
DESIGN
Population based cohort study.
SETTING
Danish national registers.
PARTICIPANTS
905 383 liveborn singletons born during 1998-
2012 in Denmark and followed from birth until July 
2014, death, emigration, or date of first psychiatric 
diagnosis, whichever came first. The children were 
followed for a maximum of 16.5 years and contributed 
8.1×106 person years at risk.
EXPOSURES FOR OBSERVATIONAL STUDIES
Children were categorised into four groups 
according to maternal antidepressant use within 
two years before and during pregnancy: unexposed, 
antidepressant discontinuation (use before but not 
during pregnancy), antidepressant continuation (use 
both before and during pregnancy), and new user (use 
only during pregnancy).
MAIN OUTCOME MEASURE
First psychiatric diagnosis in children, defined as first 
day of inpatient or outpatient treatment for psychiatric 
disorders. Hazard ratios of psychiatric disorders were 
estimated using Cox regression models.
RESULTS
Overall, psychiatric disorders were diagnosed in 
32 400 children. The adjusted 15 year cumulative 
incidence of psychiatric disorders was 8.0% (95% 
confidence interval 7.9% to 8.2%) in the unexposed 
group, 11.5% (10.3% to 12.9%) in the antidepressant 
discontinuation group, 13.6% (11.3% to 16.3%) 
in the continuation group, and 14.5% (10.5% to 
19.8%) in the new user group. The antidepressant 
continuation group had an increased risk of 
psychiatric disorders (hazard ratio 1.27, 1.17 to 1.38), 
compared with the discontinuation group.
CONCLUSIONS
In utero exposure to antidepressants was associated 
with increased risk of psychiatric disorders. The 
association may be attributable to the severity of 
underlying maternal disorders in combination with 
antidepressant exposure in utero. The findings 
suggest that focusing solely on a single psychiatric 
disorder among offspring in studies of in utero 
antidepressant exposure may be too restrictive.
Introduction
Antidepressants have been increasingly used during 
pregnancy in the past few decades,1 with approximately 
2-8% of pregnant women receiving this treatment.1-7 
Selective serotonin reuptake inhibitors (SSRIs) are 
the most commonly prescribed antidepressants.16 
Although most studies on the safety of SSRI treatment 
during pregnancy are reassuring,8-11 some recent 
studies have raised concerns about behavioural 
problems in the offspring.2 12-17
So far, population based studies of long term neu-
rodevelopmental outcomes have focused primarily on 
autism spectrum disorder in children exposed to SSRIs 
in utero. Some studies reported an increased risk,13-16 
whereas others suggested no association.2 3 7 9 12 18 19 
The magnitude of the relative risk of autism spectrum 
disorder for in utero exposure to SSRIs compared with 
non-exposure ranges from 0.83 to 3.34.2 3 7 9 12-16 18 19 
Findings on in utero exposure to SSRIs and atten-
tion-deficit/hyperactivity disorder (ADHD) are also 
contradictory; in utero SSRI exposure was associated 
with increased risk of ADHD in one study,12 but not in 
others.2 19-21 The underlying mechanism linking in ute-
ro SSRI exposure and behavioural problems is unclear; 
however, one theory posits that SSRIs cross the pla-
cental barrier and affect fetal brain development.22-26 
If this theory holds true, in utero SSRI exposure may 
increase risks of other psychiatric disorders as well as 
autism spectrum disorder and ADHD. This assumption 
is supported by two recent studies investigating other 
diagnostic groups of psychiatric disorders in children 
and adolescents besides autism spectrum disorder and 
ADHD, including depression, anxiety, neurobehav-
ioural and social development, and speech, scholastic, 
and motor disorders.2 17 Malm et al found an increased 
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WhAT IS AlReAdy knoWn on ThIS TopIC
Several studies have linked selective serotonin reuptake inhibitor use during 
pregnancy to autism spectrum disorder in offspring, although results have been 
conflicting
The potential explanation for this association is that selective serotonin reuptake 
inhibitors cross the placental barrier and affect the development of the fetal 
brain
If this holds true, in utero exposure to selective serotonin reuptake inhibitor 
and other classes of antidepressants may increase risk for various psychiatric 
disorders besides autism spectrum disorder
WhAT ThIS STudy AddS
Antidepressant use during pregnancy was associated with increased risk for 
various diagnostic groups of psychiatric disorders in offspring
The observed associations may be attributable to the severity of underlying 
maternal psychiatric disorders in combination with in utero antidepressant 
exposure
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risk of depression but not anxiety, autism spectrum 
disorder, or ADHD in children exposed to SSRIs in ute-
ro,2 and Brown et al suggested that in utero exposure 
to SSRIs was associated with increased risks of speech 
and language disorder.17 However, these studies did 
not investigate the overall risk of psychiatric disorders, 
which is important because differentiating between 
overlapping symptoms and diagnosing specific dis-
orders are challenging in children and adolescents. 
Focusing solely on a specific disorder may be too re-
strictive. Moreover, as serotonin norepinephrine reup-
take inhibitors and some tricyclic antidepressants may 
share a serotonergic component with SSRIs and have 
a serotonin inhibition effect,27 similar effects should 
be observed with other classes of antidepressants as 
well as SSRIs. Two studies suggested that risk of au-
tism spectrum disorder in the offspring did not vary by 
classes of antidepressants.15 16 However, existing stud-
ies on the association between prenatal exposure to 
non-SSRI antidepressants and psychiatric disorders in 
offspring had limited numbers of mothers treated with 
non-SSRI antidepressants,37 13 15 16 18 20 21 preventing 
in-depth analysis. Additionally, questions about the 
timing of antidepressant treatment (first, second, or 
third trimester) and associations with various psychi-
atric disorders in the exposed offspring have remained 
unanswered. In summary, gaps remain in the knowl-
edge on antidepressant use during pregnancy and risk 
of psychiatric disorders in the offspring.
We hypothesised that if in utero exposure to 
antidepressants affected fetal brain development, such 
exposure may increase the risk for various psychiatric 
disorders. We aimed to investigate the association 
between in utero antidepressant exposure and overall 
risk of psychiatric disorders. Additionally, we examined 
risks of individual disorder subcategories including 
autism spectrum disorder, mood disorder, somatoform 
disorder, behavioural disorder, and mental retardation, 
accounting for the timing and duration of treatment as 
well as the class of antidepressant.
Methods
Study population
We did a population based cohort study using data 
from Danish national registers building on the data 
from the Danish Civil Registration System.28 All live 
births and residents in Denmark are assigned a unique 
identification number that permits linkage of individual 
level data. We identified all liveborn singletons during 
1998-2012 (n=923 416) from the Danish Medical 
Birth Registry.29 We excluded 6569 children who 
had missing or likely errors in gestational age (<154 
or >315 days) and 1719 children with chromosomal 
abnormalities (ICD-10 (international classification of 
diseases, 10th revision) codes Q90-Q99) identified 
from the Danish National Patient Register.30 We further 
excluded 9745 children with missing links to their 
fathers. We included a total of 905 383 singletons born 
to 548 885 mothers (fig 1).
Antidepressant use
Information on antidepressant use came from the 
Danish National Prescription Registry.31 This register 
covers all prescriptions dispensed in Denmark 
since 1995. It contains the anatomical therapeutic 
chemical (ATC) classification codes, the number 
of defined daily doses per package, the number of 
packages dispensed, and the dispensing date. The ATC 
code for SSRIs was N06AB, and those for non-SSRI 
antidepressants were N06AA, N06AF, N06AG, and 
N06AX (see supplementary table A for detailed ATC 
codes). We used the dispensing date to indicate the 
start of antidepressant use. We defined antidepressant 
use during pregnancy as a prescription dispensed 
on any date from one month before pregnancy until 
delivery. We used the first day of the mother’s last 
menstrual period to indicate the start of pregnancy. To 
capture recent episodes in the mothers, we included 
antidepressant prescriptions dispensed from two 
years before pregnancy to delivery. We categorised the 
children into four mutually exclusive groups according 
Antidepressant use before pregnancy (n=47 639)No antidepressant use before pregnancy (n=857 744)
Liveborn singletons during 1998-2012 in Denmark (n=923 416)
Singletons born by 548 885 mothers (n=905 383)
Continuation group (n=17 560)
Antidepressant use both
before and during pregnancy 
Discontinuation group
(n=30 079)
Antidepressant use before
but not during pregnancy 
New user group (n=3503)
Antidepressant use
during pregnancy only 
Unexposed group (n=854 241)
No antidepressant use
before or during pregnancy 
Excluded (n=18 033):
  Children with missing or likely errors in gestational age (n=6569)
  Children who had chromosomal abnormalities
    (ICD-10 codes Q90-99) (n=1719)
  Children with missing links to their fathers (n=9745)
Fig 1 | Flowchart showing identification of study population. Antidepressant use before pregnancy was defined as 
prescription on any date between two years and one month before pregnancy. Antidepressant use during pregnancy 
was defined as prescription dispensed on any date from one month before pregnancy until delivery
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to dispensing of an antidepressant prescription to the 
mother from two years to one month before pregnancy 
(hereinafter referred to as before pregnancy) and 
during pregnancy (fig 1). The unexposed group had 
no maternal antidepressant use before or during 
pregnancy, the discontinuation group had use before 
but not during pregnancy, the continuation group had 
use both before and during pregnancy, and the new 
user group had use only during pregnancy.
We calculated the number of days exposed per 
prescription by multiplying the number of defined daily 
doses per package by the number of packages dispensed. 
We calculated the exact number of days exposed by 
adding the durations of all antidepressant prescriptions.
Primary and secondary outcomes: any psychiatric 
disorders and subcategories of psychiatric 
disorders
Information on psychiatric diagnosis came from 
the Danish Psychiatric Central Research Register.32 
This register holds information on all inpatient and 
outpatient psychiatric treatment in Denmark. Our 
primary outcome was first diagnosis of psychiatric 
disorders (ICD-10 codes F00-F99) in the offspring. 
We further specified the following subcategories 
of psychiatric disorders as secondary outcomes: 
autism spectrum disorder (F84.0, F84.1, F84.5, 
F84.8, or F84.9); mood disorder (F30-F39); neurotic, 
stress related, and somatoform disorder (F40-F48); 
behavioural and emotional disorder (F90-F98); 
and mental retardation (F70-F79). We chose the 
subcategory of autism spectrum disorder on the basis 
of previous work in this area. The other four categories 
were defined on the basis of the most commonly 
observed ICD-10 chapters in our study population.
Potential confounders
We included the following potential confounders in 
our analyses on the basis of causal diagrams using 
directed acyclic graphs: maternal and paternal psychi-
atric history at delivery, retrieved from the Danish Psy-
chiatric Central Research Register (ICD-8 codes 290-
351; ICD-10 codes F00-F99); maternal age at delivery 
(continuous variable); primiparity (yes/no); inpatient 
and outpatient psychiatric treatment from two years 
before pregnancy until delivery (yes/no); prescriptions 
for other psychotropic drugs (ATC codes N05 and N06 
excluding N06A) during pregnancy (yes/no); prescrip-
tions for antiepileptic drugs (ATC code N03) during 
pregnancy (yes/no); number of non-psychiatric hospi-
tal visits during pregnancy (0-1, 2-3, or ≥4); smoking 
during pregnancy (yes/no); place of residence (capital 
or capital suburb, provincial city or town, or rural ar-
eas); marital status (married or cohabiting/single, di-
vorced, or widowed); highest education (elementary 
school/above elementary school); income status (low-
est quarter/above lowest quarter); and calendar year of 
delivery (1998-2002, 2003-07, or 2008-12). Data on 
these covariates came from the registers mentioned 
above as well as from Statistics Denmark’s registers on 
socioeconomic status.33
Statistical analysis
We used Stata 13.1 for statistical analyses. We 
followed each child from birth until July 2014, 
death, emigration, or the date of first psychiatric 
diagnosis, whichever came first. For each diagnostic 
group of psychiatric disorders (secondary outcomes), 
we defined the date of first diagnosis as the first 
day of inpatient or outpatient treatment that led to 
the assignment of the specific diagnosis. We used 
Cox regression models to calculate hazard ratios 
with 95% confidence intervals, with child’s age 
as the time scale. We evaluated proportionality by 
visually inspecting “log-log” plots. A woman could 
contribute more than one pregnancy to the analyses. 
To account for the dependence between siblings, we 
used the Huber sandwich estimator for correction of 
standard errors. All P values were based on Wald’s 
tests, and we considered P<0.05 (two sided test) to 
be statistically significant. About 6.1% of the values 
were missing for any of the potential confounders, 
and we consequently applied 20 imputations by 
using the Markov Chain Monte Carlo technique for 
imputing missing values.34
We assigned a weight to each child as the estimat-
ed inverse probability of being in a certain group. We 
estimated the weights as predicted values from logis-
tic regression models with adjustment for covariates 
mentioned above.35 We used unadjusted and inverse 
probability weight adjusted Kaplan-Meier curves to 
illustrate the cumulative incidence of psychiatric dis-
orders in four groups. To evaluate whether the under-
lying maternal psychiatric disorders were associated 
with offspring psychiatric disorders, we calculated the 
hazard ratios with the unexposed group as the refer-
ence group.
Comparisons between antidepressant continuation 
and discontinuation groups
To further control for the underlying maternal psychi-
atric disorders, we did detailed analyses comparing the 
antidepressant continuation group with the discontin-
uation group, adjusting for the above mentioned covar-
iates. We estimated the population attributable frac-
tion by using the adjusted hazard ratio of psychiatric 
disorders in the continuation group versus the discon-
tinuation group and the prevalence of continued an-
tidepressant treatment during pregnancy in the entire 
population (PE) according to the formula: population 
attributable fraction=PE×(HR−1)/(PE×(HR−1)+1). The 
population attributable fraction denotes the propor-
tion of psychiatric cases in our population that could 
have been prevented if mothers from the continuation 
group had discontinued antidepressant treatment, as-
suming the association to be causal and no confound-
ing of the exposure-disease association.36
To examine whether the associations between 
antidepressant exposure and psychiatric disorders 
depended on the timing of exposure, we divided the 
exposure window into three groups based on the last 
menstrual period: first trimester only (one month before 
pregnancy to 90 days after last menstrual period); 
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second or third trimester only (91-180 days after last 
menstrual period or 181 days after last menstrual 
period to childbirth); and more than one trimester. We 
considered a child to be exposed to antidepressants in 
a specific trimester if the dispensing date fell within the 
trimester or if the number of days prescribed overlapped 
that trimester. To study whether the associations 
varied with different classes of antidepressants, 
we categorised antidepressant treatment into SSRI 
monotherapy, non-SSRI antidepressant monotherapy, 
and both SSRI and non-SSRI antidepressant treatment. 
To determine whether the associations were modified 
by the duration of use, we divided the duration of 
antidepressant use during pregnancy into 90 days 
or less, 91-180 days, and 181 days or more. We also 
included the duration as a continuous variable, per 30 
day increase, in the models to see whether duration-
response relations existed.
Sensitivity analysis
To test the robustness of our results, we did seven sen-
sitivity analyses. Firstly, to reduce the misclassification 
of antidepressant exposure, we restricted our analyses 
to mothers who filled at least two prescriptions for an-
tidepressants during pregnancy. We did this to exclude 
mothers who possibly decided not to take antidepres-
sants in pregnancy and hence did not renew their pre-
scriptions. Secondly, to reduce the misclassification of 
discontinuation of antidepressant use, we redefined 
antidepressant discontinuation as maternal use of 
antidepressant from two years to three months before 
pregnancy but not from three months before pregnan-
cy until delivery. Thirdly, to overcome any concerns 
about the validity of psychiatric diagnoses, we repeat-
ed our analysis by redefining psychiatric disorders in 
offspring as at least two hospital contacts for psychiat-
ric disorders in the register, thereby defining a stricter 
phenotype. Fourthly, mothers who had inpatient psy-
chiatric treatment may have more severe symptoms. To 
further account for the confounding by the underlying 
indication for treatment, we repeated our analyses by 
excluding 2644 pregnancies in mothers with any inpa-
tient psychiatric treatment from two years before preg-
nancy until the delivery. Fifthly, to examine whether 
the associations between maternal antidepressant use 
and psychiatric disorders in offspring were confound-
ed by shared environmental or genetic variables, we 
included comparisons with associations between pa-
ternal antidepressant use and psychiatric disorders 
in offspring.37 We further adjusted for maternal anti-
depressant use during pregnancy (unexposed, discon-
tinuation, continuation, or new user group), paternal 
age at delivery (continuous variable), and paternal 
inpatient or outpatient psychiatric treatment from two 
years before pregnancy to delivery (yes/no). Our work-
ing hypothesis was that if any potential effects are due 
to an intrauterine exposure, maternal antidepressant 
use during pregnancy should have a greater influence 
than paternal antidepressant use during the index 
pregnancy.37 Sixthly, to test whether the associations 
were modified by maternal psychiatric history, we re-
peated our analyses stratified by maternal psychiatric 
history. Finally, we investigated potential sex specific-
ity of associations by inclusion of an interaction term 
between sex of the child and antidepressant exposure.
Patient involvement
No patients were involved in setting the research ques-
tion or the outcome measures, nor were they involved 
in developing plans for design or implementation of 
the study. No patients were asked to advise on inter-
pretation or writing up of results. There are no plans 
to disseminate the results of the research to study pa-
tients or the relevant patient community.
Results
Table 1 lists socioeconomic, psychiatric, and 
demographic characteristics of the study population. 
Of the 905 383 children, 21 063 (2.3%) were born to 
mothers who used antidepressants during pregnancy. 
Approximately 1.8% (n=16 154) of mothers used 
SSRI monotherapy, 0.4% (n=3295) used non-SSRI 
antidepressant monotherapy, and 0.2% (n=1614) 
used both SSRI and non-SSRI antidepressants 
(supplementary table A). The children were followed 
for a maximum of 16.5 years and contributed 8.1×106 
person years at risk. Overall, 32 400 children were 
diagnosed as having psychiatric disorders. The mean 
age at first psychiatric diagnosis was 8.5 (SD 3.6) 
years. The weighted 15 year cumulative incidence 
of psychiatric disorders in the offspring was 8.0% 
(95% confidence interval 7.9% to 8.2%) for the 
unexposed group, 11.5% (10.3% to 12.9%) for the 
discontinuation group, 13.6% (11.3% to 16.3%) for 
the continuation group, and 14.5% (10.5% to 19.8%) 
for the new user group (fig 2). We observed increased 
risks of psychiatric disorders in all three groups of 
antidepressant users (discontinuation, continuation, 
and new user groups), compared with the unexposed 
group (supplementary figure).
Comparisons between antidepressant continuation 
and discontinuation groups
The risk for psychiatric disorders among offspring in 
the continuation group was higher than that in the 
discontinuation group (hazard ratio 1.27, 95% confi-
dence interval 1.17 to 1.38). This was apparent after 
adjustment for demographic and psychiatric charac-
teristics of the mothers, including inpatient and outpa-
tient psychiatric treatment and comorbid psychotropic 
drug use (table 2). The population attributable fraction 
was 0.5%, indicating that continuous antidepressant 
use during pregnancy explained 0.5% of psychiatric 
cases in the study population, assuming an uncon-
founded causal association.
Children exposed to antidepressant during the 
first trimester only had the lowest risk of psychiatric 
disorders compared with children exposed in the 
second or third trimester only or exposed during 
more than one trimester. The risk of psychiatric 
disorders did not differ between children exposed 
to SSRI monotherapy and non-SSRI antidepressant 
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monotherapy, although statistical precision was low 
for non-SSRI antidepressant monotherapy. The highest 
risk was among children whose mothers used both 
SSRI and non-SSRI antidepressants (hazard ratio 1.72, 
1.40 to 2.11). We found no marked differences in the 
hazard ratios of psychiatric disorders among the most 
commonly prescribed SSRIs, although the statistical 
precision was low for paroxetine and escitalopram. The 
hazard ratios were 1.32 (1.15 to 1.51) for citalopram 
monotherapy, 1.26 (1.05 to 1.51) for sertraline, 1.22 
(1.02 to 1.45) for fluoxetine, 1.17 (0.94 to 1.46) for 
paroxetine, and 1.14 (0.78 to 1.68) for escitalopram, 
compared with the discontinuation group. For different 
durations of antidepressant use, a higher risk was seen 
among children whose mothers took antidepressants 
for more than 180 days (hazard ratio 1.40, 1.26 to 
1.56) (table 2).
We also saw increased risks in the continuation 
group compared with the discontinuation group for 
autism spectrum disorder (hazard ratio 1.23, 1.01 to 
1.51), mood disorder (2.76, 1.59 to 4.78), somatoform 
disorder (1.62, 1.36 to 1.94), and behavioural disorder 
(1.13, 1.01 to 1.27), but not mental retardation (1.21, 
0.78 to 1.90) (table 3). The hazard ratios of specific 
Table 1 | Characteristics of study population according to maternal antidepressant use before and during pregnancy. Values are numbers 
(percentages) unless stated otherwise
Characteristics
Unexposed group* 
(n=854 241)
Antidepressant discontinuation 
group† (n=30 079)
Continuation group‡ 
(n=17 560)
New user group§ 
(n=3503)
Mean (SD) maternal age at delivery, years 30.2 (4.8) 30.1 (5.2) 30.8 (5.2) 29.4 (5.6)
Primiparity 375 698 (44.0) 13 560 (45.1) 7914 (45.1) 1397 (39.9)
Maternal psychiatric history at delivery 37 410 (4.4) 9440 (31.4) 8494 (48.4) 1168 (33.3)
Inpatient psychiatric treatment from 2 years before pregnancy to 
delivery
1796 (0.2) 1296 (4.3) 1348 (7.7) 184 (5.3)
Outpatient psychiatric treatment from 2 years before pregnancy 
to delivery
8939 (1.0) 4871 (16.2) 5006 (28.5) 806 (23.0)
Dispensing of other psychotropic prescriptions during pregnancy 4816 (0.6) 656 (2.2) 1140 (6.5) 468 (13.4)
Dispensing of antiepileptic prescriptions during pregnancy 231 (<0.1) 34 (0.1) 75 (0.4) 21 (0.6)
No of non-psychiatric hospital visits during pregnancy:
 0-1 202 879 (23.7) 4616 (15.3) 2577 (14.7) 515 (14.7)
 2-3 428 562 (50.2) 13 349 (44.4) 7750 (44.1) 1492 (42.6)
 ≥4 222 800 (26.1) 12 114 (40.3) 7233 (41.2) 1496 (42.7)
Maternal smoking during pregnancy:
 Yes 137 089 (16.0) 8867 (29.5) 5325 (30.3) 1180 (33.7)
 No 694 874 (81.3) 20 431 (67.9) 11 743 (66.9) 2224 (63.5)
 Missing 22 278 (2.6) 781 (2.6) 492 (2.8) 99 (2.8)
Place of residence at delivery:
 Capital or capital suburb 254 423 (29.8) 7262 (24.1) 4160 (23.7) 798 (22.8)
 Provincial city or town 334 536 (39.2) 12 600 (41.9) 7679 (43.7) 1491 (42.6)
 Rural areas 265 173 (31.0) 10 216 (34.0) 5719 (32.6) 1212 (34.6)
 Missing¶ 109 (<0.1) <5 (<0.1) <5 (<0.1) <5 (<0.1)
Maternal marital status at delivery:
 Married or cohabiting 752 769 (88.1) 23 630 (78.6) 13 646 (77.7) 2673 (76.3)
 Single, divorced, or widowed 101 472 (11.9) 6449 (21.4) 3914 (22.3) 830 (23.7)
Maternal highest education at delivery:
 Elementary school 151 931 (17.8) 9966 (33.1) 5262 (30.0) 1337 (38.2)
 Above elementary school 671 138 (78.6) 19 547 (65.0) 12 001 (68.3) 1997 (57.0)
 Missing 31 172 (3.6) 566 (1.9) 297 (1.7) 169 (4.8)
Maternal income status at delivery:
 Lowest quarter 141 866 (16.6) 6534 (21.7) 4449 (25.3) 752 (21.5)
 Above lowest quarter 712 120 (83.4) 23 544 (78.3) 13 110 (74.7) 2750 (78.5)
 Missing¶ 255 (<0.1) <5 (<0.1) <5 (<0.1) <5 (<0.1)
Calendar year of delivery:
 1998-2002 302 651 (35.4) 5707 (19.0) 2297 (13.1) 650 (18.6)
 2003-07 287 096 (33.6) 10 578 (35.1) 5778 (32.9) 1270 (36.3)
 2008-12 264 494 (31.0) 13 794 (45.9) 9485 (54.0) 1583 (45.2)
Paternal psychiatric history at delivery 30 257 (3.5) 2587 (8.6) 1676 (9.5) 324 (9.2)
Paternal antidepressant use:
 No antidepressant use 821 716 (96.2) 27 034 (89.9) 15 298 (87.1) 3083 (88.0)
 Use before but not during pregnancy 13 385 (1.6) 1377 (4.6) 784 (4.5) 161 (4.6)
 Use both before and during pregnancy 11 984 (1.4) 1098 (3.7) 1078 (6.1) 152 (4.3)
 Use during but not before pregnancy 7156 (0.8) 570 (1.9) 400 (2.3) 107 (3.1)
Sex of child:
 Male 438 176 (51.3) 15 553 (51.7) 9070 (51.7) 1829 (52.2)
 Female 416 065 (48.7) 14 526 (48.3) 8490 (48.3) 1674 (47.8)
*Children whose mothers did not use antidepressant before or during pregnancy.
†Children whose mothers used antidepressants before but not during pregnancy.
‡Children whose mothers used antidepressants both before and during pregnancy.
§Children whose mothers used antidepressants during but not before pregnancy.
¶To comply with Danish regulations aimed at safeguarding anonymity of people included in register based research studies, numbers less than 5 cannot be shown.
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diagnostic groups of psychiatric disorders according to 
timing, class, and duration of antidepressant use are 
shown in supplementary tables B–D.
Sensitivity analyses
Among mothers who continued antidepressant use 
during pregnancy, 74.4% (n=13 056) received two 
or more prescriptions. Redefining antidepressant 
exposure as two prescriptions gave a hazard 
ratio of psychiatric disorders for the continuation 
group of 1.33 (1.21 to 1.46), compared with the 
discontinuation group (supplementary table E). 
Sensitivity analyses showed similar results when 
we redefined antidepressant discontinuation as 
use of antidepressants before pregnancy with no 
use from three months before pregnancy until 
delivery or excluded pregnancies in mothers with 
inpatient psychiatric treatment from two years 
before pregnancy until delivery (supplementary 
tables F and G). When we redefined psychiatric 
disorders in offspring as at least two hospital 
contacts for psychiatric disorders, 17 735 children 
were categorised as having psychiatric disorders. 
The result remained unchanged, with a hazard ratio 
of 1.20 (1.06 to 1.35) for the continuation group 
versus the discontinuation group. We found that 
paternal antidepressant use during pregnancy was 
associated with overall psychiatric, somatoform, and 
behavioural disorders, but not other diagnostic groups 
of psychiatric disorders. The associations between 
paternal antidepressant use and psychiatric disorders 
in offspring were weaker than the associations 
between maternal antidepressant use and psychiatric 
disorders in offspring (supplementary figure). 
The associations between in utero antidepressant 
exposure and psychiatric disorders were slightly but 
not statistically significantly higher among children 
born to mothers with a psychiatric history than in 
children born to mothers with no psychiatric history 
(supplementary table H). We found no evidence 
to suggest that the associations between in utero 
antidepressant exposure and psychiatric disorders 
were modified by sex of the child (all P values for 
interaction were greater than 0.2).
discussion
We observed increased risks for psychiatric disorders 
among children of mothers who used antidepressants 
before and/or during pregnancy, compared with moth-
ers with no record of antidepressant use. Furthermore, 
we observed an increased risk of psychiatric disorders 
in children whose mothers continued antidepressant 
use during pregnancy, compared with mothers who 
discontinued. These associations could be attributable 
to the severity of the underlying maternal disorders in 
combination with in utero antidepressant exposure.5
We found that children whose mothers discontin-
ued antidepressant use also had an increased risk of 
psychiatric disorders. This association is most likely 
driven by the underlying maternal psychiatric disor-
ders, which may be transmitted to offspring via shared 
genetic susceptibility, environmental stress, and/or 
parenting practices.383940 We did observe an increased 
risk of psychiatric disorders among children exposed 
to antidepressants in utero. We speculated that this in-
creased risk could be due to the severity of underlying 
maternal psychiatric disorders because mothers with 
severe symptoms are more likely to continue treatment 
during pregnancy.5
We tried to account for the underlying disorders by 
adjusting for various psychiatric variables including 
maternal and paternal psychiatric history, dispensing 
of prescriptions for antiepileptic and other psycho-
tropic drugs during pregnancy, and inpatient and out-
patient psychiatric treatment before pregnancy. After 
adjustment, the increased risk of psychiatric disorders 
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Fig 2 | Crude and adjusted Kaplan-Meier curves 
illustrating cumulative incidence of any psychiatric 
disorders in children according to maternal 
antidepressant use before and during pregnancy 
(n=905 383). Unexposed group: children whose mothers 
did not use antidepressant before or during pregnancy. 
Antidepressant discontinuation group: children whose 
mothers used antidepressants before but not during 
pregnancy. Antidepressant continuation group: children 
whose mothers used antidepressants both before and 
during pregnancy. New user group: children whose 
mothers used antidepressants during but not before 
pregnancy. Adjusted for maternal age at delivery, 
primiparity, maternal psychiatric history at delivery, 
inpatient and outpatient psychiatric treatment from 
two years before pregnancy until delivery, dispensing 
of other psychotropic prescriptions during pregnancy, 
dispensing of antiepileptic prescriptions during 
pregnancy, number of non-psychiatric hospital visits 
during pregnancy, smoking during pregnancy, place of 
residence, marital status, highest education, income, 
calendar year of delivery, and paternal psychiatric history 
at time of delivery
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in offspring remained statistically significant, but the 
magnitude of the association was attenuated.
In a next step, we repeated all our analyses for pa-
ternal antidepressant use during the index pregnancy, 
with psychiatric disorders in offspring as the outcome. 
We found that continuous paternal antidepressant use 
during pregnancy was also associated with slightly 
increased risk of overall psychiatric disorders in off-
spring, but a stronger association was observed for ma-
ternal antidepressant use. For somatoform disorder, 
the influence was similar for maternal and paternal 
antidepressant exposure. For other diagnostic groups 
of psychiatric disorders, significant differences were 
observed as the confidence intervals of these estimates 
did not overlap. The observed differences in results 
for maternal versus paternal antidepressant use may 
indicate an intrauterine effect over and beyond any 
shared genetic, familial, or environmental factors.37 
Maternal antidepressant use and/or underlying dis-
orders during pregnancy may affect the intrauterine 
environment and programme fetal neurodevelopment 
via alterations of maternal hormonal and behavioural 
responses to stress, placental function and perfusion, 
fetal hypothalamic-pituitary-adrenal axis, and epige-
netic profiles, alone or in combination.41
We observed a higher risk among children whose 
mothers took antidepressants for more than 180 days, 
meaning that longer exposure periods were associated 
with higher risks. Similarly, a longer duration of 
treatment may reflect persistent symptoms in the 
mothers, and the duration of disorders predicts adverse 
neurodevelopment of offspring.42 We found that the 
risk of psychiatric disorders in offspring did not vary 
by class of antidepressants. The highest risk was 
Table 2 | Hazard ratios of any psychiatric disorders among children born to mothers with continuous antidepressant use, compared with mothers 
with discontinuous antidepressant use (n=47 639)
Antidepressant use during pregnancy Cases No Person years Crude hazard ratio Adjusted hazard ratio (95% CI)*
Antidepressant discontinuation group† 1417 30 079 2.2×105 1 1 (reference)
Antidepressant continuation group‡ 944 17 560 1.2×105 1.40 1.27 (1.17 to 1.38)
Timing of antidepressant use:
 Use in first trimester only 249 3772 3.0×104 1.21 1.16 (1.01 to 1.33)
 Use in second or third trimester only 36 575 3.8×103 1.61 1.42 (1.02 to 1.97)
 Use in more than one trimester 659 13 213 8.1×104 1.48 1.32 (1.20 to 1.45)
Class of antidepressant use:
 SSRI monotherapy 722 13 501 9.0×104 1.36 1.25 (1.14 to 1.37)
 Non-SSRI antidepressant monotherapy 119 2610 1.6×104 1.26 1.15 (0.96 to 1.40)
 Use both SSRI and non-SSRI antidepressants 103 1449 9.0×103 2.05 1.72 (1.40 to 2.11)
Duration of antidepressant use:
 ≤90 days 263 4075 3.2×104 1.20 1.15 (1.01 to 1.31)
 91–180 days 184 3504 2.3×104 1.32 1.18 (1.01 to 1.38)
 ≥181 days 497 9981 6.0×104 1.57 1.40 (1.26 to 1.56)
 Per 30 day increase – – – 1.03 1.02 (0.99 to 1.06)
SSRI=selective serotonin reuptake inhibitor.
*Adjusted for maternal age at delivery, primiparity, maternal psychiatric history at delivery, inpatient and outpatient psychiatric treatment from 2 years before pregnancy until delivery, 
dispensing of other psychotropic prescriptions during pregnancy, dispensing of antiepileptic prescriptions during pregnancy, number of non-psychiatric hospital visits during pregnancy, 
smoking during pregnancy, place of residence, marital status, highest education, income, calendar year of delivery, and paternal psychiatric history at time of delivery.
†Children whose mothers used antidepressants before but not during pregnancy; used as comparison group for all comparisons.
‡Children whose mothers used antidepressants both before and during pregnancy.
Table 3 | Hazard ratios of specific psychiatric disorders among children born to mothers with continuous antidepressant use, compared with 
mothers with discontinuous antidepressant use (n=47 639)
Antidepressant use during pregnancy* Cases No Person years Crude hazard ratio Adjusted hazard ratio (95% CI)†
Autism spectrum disorder:
 Antidepressant discontinuation group 257 30 079 2.2×105 1 1 (reference)
 Antidepressant continuation group 165 17 560 1.2×105 1.32 1.23 (1.01 to 1.51)
Mood disorder:
 Antidepressant discontinuation group 26 30 079 2.2×105 1 1 (reference)
 Antidepressant continuation group 27 17 560 1.2×105 2.72 2.76 (1.59 to 4.78)
Neurotic, stress related, and somatoform disorder:
 Antidepressant discontinuation group 276 30 079 2.2×105 1 1 (reference)
 Antidepressant continuation group 249 17 560 1.2×105 1.92 1.62 (1.36 to 1.94)
Behavioural and emotional disorder:
 Antidepressant discontinuation group 789 30 079 2.2×105 1 1 (reference
 Antidepressant continuation group 470 17 560 1.2×105 1.24 1.13 (1.01 to 1.27)
Mental retardation:
 Antidepressant discontinuation group 53 30 079 2.2×105 1 1 (reference)
 Antidepressant continuation group 33 17 560 1.2×105 1.25 1.21 (0.78 to 1.90)
*Antidepressant discontinuation group=children whose mothers used antidepressants before but not during pregnancy; antidepressant continuation group=children whose mothers used 
antidepressants both before and during pregnancy.
†Adjusted for maternal age at delivery, primiparity, maternal psychiatric history at delivery, inpatient and outpatient psychiatric treatment from 2 years before pregnancy until delivery, dispensing 
of other psychotropic prescriptions during pregnancy, dispensing of antiepileptic prescriptions during pregnancy, number of non-psychiatric hospital visits during pregnancy, smoking during 
pregnancy, place of residence, marital status, highest education, income, calendar year of delivery, and paternal psychiatric history at time of delivery.
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observed among children exposed to both SSRI and 
non-SSRI antidepressants, indicating that the mothers 
were treated with polypharmacy or switched drugs. 
Mothers may be treated with polypharmacy or switch 
drugs because of limited/absent treatment response or 
psychiatric comorbidities,43 44 consequently exposing 
the fetus to insufficiently managed underlying 
maternal disorders. We also found a higher risk among 
children whose mothers used antidepressants in the 
second or third trimester only and for whom the drugs 
were prescribed across more than one trimester. We 
hypothesise that these findings can also be attributed 
to the severity of maternal symptoms, as mothers 
may restart antidepressants in the second and third 
trimester because of severe psychiatric symptoms or 
relapse.43
Findings on specific diagnostic groups of 
psychiatric disorders
In this study, in utero exposure to antidepressants was 
associated with a marginally elevated risk of autism 
spectrum disorder and behavioural disorder including 
ADHD. Studies on this topic are inconsistent,2 3 7 9 12-16 18-21 
which makes treatment decisions challenging for in-
dividual women and their treating physicians. Recent-
ly, two studies reported an increased risk of autism 
spectrum disorder after exposure to antidepressant in 
utero in the population cohort but not in the sibling 
comparison.7 19 Although a sibling design provides 
one efficient approach to control for time stable famil-
ial factors, sibling comparisons are subject to several 
limitations including highly selected populations, 
non-shared confounding bias, and by default smaller 
sample size.45 Thereby, any interpretation based solely 
on sibling comparisons is complicated. On the basis of 
our findings and previous findings, the observed asso-
ciations of in utero antidepressant exposure with au-
tism spectrum disorder and behavioural disorder are 
modest, if they exist.
We found a strong association between maternal 
antidepressant use during pregnancy and mood 
disorder in the offspring. This is in line with a recent 
study using Finnish national registers.2 Despite 
the association observed in two large independent 
datasets, no evidence exists in humans to show that 
antidepressant use causes vulnerability for mood 
disorder in offspring. In contrast, experimental animal 
studies showed that prenatal exposure to SSRIs led 
to increased depression and anxiety-like behaviour, 
decreased sociability, and impaired learning.232546 
Moreover, in animal models, intrauterine SSRI exposure 
altered hormonal and behavioural responses to stress 
and induced epigenetic changes.41 The rationale for 
these results could be the fact that serotonin acts as 
a trophic factor, particularly in those brain systems 
that modulate emotional function.41 Serotonin has 
an influence on several developmental processes 
such as neuronal differentiation, migration, and 
synaptogenesis. Consequently, early manipulation of 
the serotonergic system could contribute to emotional 
disorders in offspring.
Clinical implications: antidepressant continuation 
or discontinuation during pregnancy?
We found an association between antidepressant use 
during pregnancy and psychiatric disorders in off-
spring, and the corresponding population attributable 
fraction was 0.5%. From a public health perspective, 
this indicates that 0.5% of psychiatric disorders in our 
population could have been prevented if mothers in 
the antidepressant continuation group had not taken 
antidepressants during pregnancy, although only if 
the association is causal and antidepressant exposure 
is independent from other factors that influence psy-
chiatric disorders.36
The decision to discontinue or maintain antide-
pressant treatment during pregnancy is challenging. 
Discontinuation of antidepressant treatment can lead 
to psychiatric episodes with subsequent long lasting 
adverse effects on both the mother and child.47 Con-
versely, discontinuation of antidepressants might be 
an option for a subgroup of women.48 Decision making 
tools and treatment algorithms to identify subgroups 
of women who can be tapered off antidepressants safe-
ly are urgently needed. Clinical guidelines are availa-
ble, including a review from the American Psychiatric 
Association and the American Association of Obstetri-
cians and Gynecologists.48 This review concludes that 
patients with no or mild depressive symptoms during 
a six month period may be candidates for discontin-
uation before conception. In contrast, patients with 
a history of severe, recurrent depression may not be 
suitable candidates for drug discontinuation before 
or during pregnancy. The findings of our study do not 
change these recommendations. Importantly, any final 
decision on antidepressant continuation should be in-
dividualised and made jointly by health professionals 
and patients.
Strengths and limitations of study
We examined a wide range of psychiatric disorders 
with a large sample size, allowing evaluation of the 
associations between particular classes of antidepres-
sants and specific diagnostic groups of psychiatric 
disorders. Information on antidepressant use and psy-
chiatric diagnoses were collected prospectively, which 
reduces the chance of recall bias. Our study has a fol-
low-up period up to 16.5 years, which enabled us to 
investigate long term outcomes.
Our study also has limitations. Firstly, we used pre-
scription data to define antidepressant exposure. As 
some patients who filled prescriptions may not take 
the antidepressants, we might have misclassified them 
as exposed. However, compliance with antidepressant 
treatment during pregnancy is high in Denmark,49 so 
any misclassification is likely to be limited. Further-
more, we obtained similar results when we redefined 
antidepressant exposure on the basis of two prescrip-
tions. We estimated the duration of antidepressant 
treatment as the number of defined daily doses, a 
measure defined by the World Health Organization, re-
lating to the average amount of a drug needed for long 
term therapeutic use. However, prescribed daily doses 
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might differ,50 which can lead to potential misclassifi-
cation of duration of treatment. This misclassification 
would have biased our estimate of the effect of differ-
ent durations of treatment on psychiatric disorders in 
offspring towards each other.
Secondly, we used the date of first psychiatric 
treatment as first psychiatric diagnosis. Mothers 
who take antidepressants may be more likely to seek 
treatment for their children, which could introduce 
detection bias. However, we investigated several 
diagnostic groups of psychiatric disorders, some of 
which have a later onset.51 Similar associations were 
observed irrespective of age at onset. Therefore we 
doubt that our findings can be ascribed to detection 
bias. Furthermore, children with one hospital contact 
for psychiatric disorders may have transient conditions. 
To overcome this potential misclassification of our 
outcome, we repeated our analysis by redefining 
psychiatric disorders in offspring by at least two 
hospital contacts for psychiatric disorders, but similar 
results were obtained.
Thirdly, mothers who took antidepressants may 
have more severe underlying disorders than non-
users. Although we attempted to control for the 
underlying indication, confounding by severity may 
still occur. Fourthly, this is an observational study, 
and unmeasured confounding is always a concern in 
these types of studies. We were unable to include some 
important covariates, such as alcohol consumption, 
which are not available in the registers. Fifthly, 
although our study has a large sample size, some 
subgroup analyses are based on quite small numbers 
of cases. Lastly, although our findings suggest an 
association between in utero antidepressant exposure 
and psychiatric disorders in offspring, our results do 
not confirm causality.
Conclusion
Antidepressant use during pregnancy was associated 
with increased risk of psychiatric disorders in offspring. 
The association may be attributable to the severity of 
underlying maternal disorders in combination with 
antidepressant exposure in utero. Our findings suggest 
that focusing solely on a single psychiatric disorder 
among offspring in studies of in utero antidepressant 
exposure may be too restrictive.
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